Idelalisib

Generic Name
Idelalisib
Brand Names
Zydelig
Drug Type
Small Molecule
Chemical Formula
C22H18FN7O
CAS Number
870281-82-6
Unique Ingredient Identifier
YG57I8T5M0
Background

Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituxi...

Indication

用于治疗：复发慢性淋巴细胞性白血病(CLL)，与利妥昔单抗联用，在由于其他共患病将考虑对单独利妥昔单抗适当治疗患者。复发滤泡B-细胞非霍奇金淋巴瘤(FL)接受至少2次既往全身治疗患者。复发性小淋巴细胞淋巴瘤(SLL)曾至少接受2次既往全身治疗患者。

Associated Conditions
Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed follicular B-cell non-Hodgkin's lymphoma
Associated Therapies
-
Clinical Trials
Related News

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

First Posted Date
2015-12-28
Last Posted Date
2021-12-20
Lead Sponsor
MorphoSys AG
Target Recruit Count
24
Registration Number
NCT02639910
Locations
🇬🇧

Clinical Study Site, Leeds, United Kingdom

Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

First Posted Date
2015-11-11
Last Posted Date
2020-02-24
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
20
Registration Number
NCT02603445
Locations
🇩🇪

Novartis Investigative Site, Mainz, Germany

Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis

Phase 2
Terminated
Conditions
Amyloidosis
Interventions
Drug: Idelalisib
First Posted Date
2015-10-29
Last Posted Date
2017-09-21
Lead Sponsor
John Mark Sloan
Target Recruit Count
1
Registration Number
NCT02590588
Locations
🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

First Posted Date
2015-09-02
Last Posted Date
2020-11-25
Lead Sponsor
Gilead Sciences
Target Recruit Count
2
Registration Number
NCT02538614
Locations
🇺🇸

Ohio State University, Columbus, Ohio, United States

🇺🇸

University of Utah, Salt Lake City, Utah, United States

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Phase 3
Terminated
Conditions
Follicular Lymphoma
Interventions
Drug: Idelalisib
First Posted Date
2015-08-31
Last Posted Date
2023-08-14
Lead Sponsor
Gilead Sciences
Target Recruit Count
96
Registration Number
NCT02536300
Locations
🇬🇧

Barts Health Trust, London, United Kingdom

🇨🇿

Fakulni newmcince v Motole, Onkologicka klinika 2. LF UK a FN Motol, Praha 5, Czechia

🇦🇺

Calvary Norht Adelaide Hosptial, Woodville South, South Australia, Australia

and more 63 locations

Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma

First Posted Date
2015-06-11
Last Posted Date
2021-04-02
Lead Sponsor
Gilead Sciences
Target Recruit Count
16
Registration Number
NCT02468557
Locations
🇺🇸

Dana Farber/ Harvard Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Greenville Hospital System, Greenville, South Carolina, United States

🇺🇸

Indiana University Goshen Center for Cancer Care, Goshen, Indiana, United States

and more 6 locations

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

First Posted Date
2015-05-29
Last Posted Date
2024-10-11
Lead Sponsor
Gilead Sciences
Target Recruit Count
203
Registration Number
NCT02457598
Locations
🇬🇧

Cardiff and Vale Health Board, Clinical Research Facility, Cardiff, United Kingdom

🇺🇸

Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States

🇺🇸

Georgetown University Medical Center, Washington, District of Columbia, United States

and more 12 locations

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease

Phase 1
Terminated
Conditions
Myelofibrosis
Interventions
Drug: Idelalisib
Drug: Ruxolitinib
First Posted Date
2015-05-06
Last Posted Date
2020-09-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
10
Registration Number
NCT02436135
Locations
🇺🇸

Stanford Hospital and Clinics, Stanford, California, United States

🇺🇸

University of Michigan Health System, Ann Arbor, Michigan, United States

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

First Posted Date
2015-01-07
Last Posted Date
2024-01-03
Lead Sponsor
Mayo Clinic
Target Recruit Count
65
Registration Number
NCT02332980
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

First Posted Date
2014-10-07
Last Posted Date
2019-05-14
Lead Sponsor
Gilead Sciences
Target Recruit Count
10
Registration Number
NCT02258529
Locations
🇺🇸

Pacific Shores Medical Group, Long Beach, California, United States

🇺🇸

Prarie Lakes Health Care Systems, Inc., Watertown, South Dakota, United States

🇺🇸

St. Agnes Hospital, Baltimore, Maryland, United States

and more 3 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy